Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link GLP1 Receptor Agonist Mechanisms GLP1RAs mimic the effects of Human Glucagon Like Peptide1 (GLP1), 'fooling your body' into thinking you ingested more than you actually have, causing earlier onset fullness & eventual LY3437943, a novel triple glucagon, GIP, and GLP 1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept ScienceDirect